Edorium Journal of

Disability and Rehabilitation

 
  Table of Contents    
Case Report
 
Focal myositis with extraordinary late onset after the combined antilipidemics therapy: Risk factors management
Bartosz Bujan1,2, Elmar Ginzburg1
1MD, Clinic for Neurology, Neurologic and Orthopedic Rehabilitation MediClin Center, Bad Orb, Germany.
2MD, Neurorehabilitation, Clinic Lengg, Zurich, Switzerland.

Article ID: 100012D05BB2016
doi:10.5348/D05-2016-12-CR-8

Address correspondence to:
Bartosz Bujan
Clinic for Neurology, Neurologic and Orthopedic Rehabilitation MediClin Center
Bad Orb
Germany

Access full text article on other devices

  Access PDF of article on other devices

[HTML Abstract]   [PDF Full Text] [Print This Article]
[Similar article in Pumed] [Similar article in Google Scholar]

How to cite this article
Bujan B, Ginzburg E. Focal myositis with extraordinary late onset after the combined antilipidemics therapy: Risk factors management. Edorium J Disabil Rehabil 2016;2:66–69.


Abstract
Introduction: Statins and other antilipidemics are frequently described medications for the treatment of hypercholesterolemia to prevent cardiovascular events like heart infarctions or strokes. Statins are, conform to the German neurological guidelines, administered often independent of initial cholesterol level after stroke to prevent new relapses. Hence, we can observe in the clinical practice in our Neurologic Rehabilitation Department permanent increase in number of patients with long-term statin therapy. Although statins have side effects like deleterious effect on skeletal muscle. The most serious complications are myositis or rhabdomyolysis with kidney failure.
Case Report: We present a case report of a 51-year-old Caucasian woman with combined antilipidemics therapy who developed a focal myositis with extraordinary late onset after the cessation of drug therapy. The patient received simvastatin 40 mg per day for a couple of weeks. Due to the persistent high cholesterol level the patient received an add-on therapy with ezetimibe for 2–3 weeks. She complained about generalized muscle pains and her high level of creatine kinase 373 U/l (normal range, 0–167 U/L). The patient showed initially a good recovery with less intense pain. Nevertheless, the muscle pain did not disappear completely and six months after the cessation of statin therapy the patient revealed again an intense muscle pain and tenderness notably femoral on the right side with the very high level of CK 2694 U/l. The femoral magnetic resonance imaging (MRI) demonstrated an accentuated vascular network right and a congestion of subcutaneous and endomysial lymphatic vessels, hence this configuration implicated a focal inflammatory reaction. We diagnosed a focal myositis in view to the clinical characteristics and MRI-tests. We initiated a steroid therapy (prednisolon 1 mg/kg on total body weight). Thereby the CK level decreased dramatically. At discharge CK level decreased to 548 U/l and ESR revealed normal values 3 mm in the first hour. After three weeks of therapy with steroids we could not register any femoral induration or local tenderness any more.
Conclusion: Hence, it should be a prime concern to evaluate risk factors for statin-induced myopathy or myositis by intensive rehabilitation training.

Keywords: Antilipidemics, Exercise training, Myositis, Risk factors, Side effects, Statin


[HTML Abstract]   [PDF Full Text]

Author Contributions
Bartosz Bujan – Substantial contributions to conception and design, Acquisition of data, Analysis and interpretation of data, Drafting the article, Revising it critically for important intellectual content, Final approval of the version to be published
Elmar Ginzburg – Substantial contributions to conception and design, Revising it critically for important intellectual content, Final approval of the version to be published
Guarantor of submission
The corresponding author is the guarantor of submission.
Source of support
None
Conflict of interest
Authors declare no conflict of interest.
Copyright
© 2016 Bartosz Bujan et al. This article is distributed under the terms of Creative Commons Attribution License which permits unrestricted use, distribution and reproduction in any medium provided the original author(s) and original publisher are properly credited. Please see the copyright policy on the journal website for more information.



  Home line About the Journal line Aim and Scope line Open Access line Archives
Apply as Editor line Apply as Reviewer line Submit Reviews - Editors line Submit Reviews - Reviewers
Instructions for Authors line Templates to Use line Copyright Form line Author Checklist
Online Submission line Email Submission line Submit Revision line Submit All Forms line Submit Page Proofs
Terms of Service line Privacy policy line Disclaimer line FAQ line Contact: Journal line Contact: Edorium Journals line Site Map
 
  Copyright © 2017. Edorium. All rights reserved.